CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Difelikefalin Injectiondrug
Likely dose
Difelikefalin Injection 0,5 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05885763
NCT05885763Phase 1Completed

A Phase 1, Single-arm, Open-label Study to Evaluate the Pharmacokinetics and Safety of Intravenous Difelikefalin in Adult Chinese Subjects on Haemodialysis

Vifor Fresenius Medical Care Renal Pharma·interventional·Posted Jun 2, 2023·Updated Feb 14, 2025

In Brief

A Phase 1 clinical trial evaluating Difelikefalin Injection for End Stage Renal Disease on Hemodialysis. Completed, enrolled 30 participants across 4 sites.

Detailed Summary

This is a Phase 1, single-arm, open-label study to evaluate the safety, PK, and tolerability of a repeated (3 times weekly) dose of difelikefalin administered as IV bolus injections to adult Chinese HD subjects. Treatment period is one week and there is a safety follow-up period of 1 week.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina

Timeline

Phase 1CompletedFinished
202420252026
First PostedJun 2, 2023
Enrollment StartJun 26, 2023
Primary CompletionOct 9, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.1 years ago

Interventions

Difelikefalin Injectiondrug

Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.